Starting TRT After 50: What's Different

Men in their fifties and sixties are the population most of the TRT evidence was actually built on. TRAVERSE, the largest randomized testosterone trial ever run, enrolled 5,204 men aged 45 to 80.[1] Age itself is not a barrier to treatment. What changes after 50 is how symptoms present, how much you can trust a total testosterone number, and — following a 2024 finding — what the monitoring conversation needs to include.

Symptoms get harder to recognise, not easier

Under 40, low testosterone tends to announce itself fairly specifically: reduced libido, erectile changes, a clear drop in energy. Those prompt investigation.

After 50 the picture blurs, and every symptom has a plausible innocent explanation:

• Fatigue and reduced stamina — attributed to age, sleep, or work
• Irritability, low motivation, flattened mood — attributed to life circumstances
• Reduced mental sharpness — attributed to normal ageing
• Loss of lean mass and gain of abdominal fat, independent of diet
• Reduced libido, often a quieter complaint than in younger men

The result is systematic underdiagnosis. Men adapt to a gradual decline and reframe it as inevitable, which is exactly what makes a hormone panel worth doing rather than assuming.

Why the total testosterone number gets less trustworthy

This is the single most useful thing to understand about testing after 50.

Sex hormone-binding globulin rises with age. SHBG binds testosterone tightly enough to take it out of play, so as it climbs, a larger share of your total is unavailable to tissue. Two men with identical total testosterone can have very different amounts of usable hormone — and the older man is more likely to be the one whose free testosterone is genuinely low.

Endocrine Society guidance supports measuring free or bioavailable testosterone when total testosterone sits near the diagnostic threshold, when an SHBG abnormality is suspected, or when symptoms and total testosterone disagree.[2] All three apply more often after 50. The mechanics are covered in free vs total testosterone.

The fracture finding, stated straight

This is where a lot of older material about TRT and bone is now out of date, and the correction matters.

For years the reasonable expectation was that testosterone would protect bone — earlier work consistently showed it improved measures of bone density and structure. In 2024 a nested study within TRAVERSE tested whether that translated into fewer actual fractures. It did not. Across 5,204 men, clinical fractures occurred in 3.50% of the testosterone group versus 2.46% on placebo (hazard ratio 1.43, 95% CI 1.04–1.97) over a median 3.19 years. The investigators wrote that they "did not expect these results."[3]

Fracture rates were numerically higher in the testosterone group across every fracture endpoint examined. The trial was not designed to explain why, so the mechanism is unknown, and it did not assess falls or bone density directly.

What to do with that: it is a reason to raise fractures and fall risk with your provider when starting TRT after 50, particularly if you already have osteoporosis, a prior fragility fracture, or a history of falls. It is not a reason to assume TRT protects your bones — the best available trial evidence points the other way.

Monitoring that matters more with age

PSA and prostate. PSA is checked before starting and monitored during therapy. The concern is not that testosterone causes prostate cancer; it is that treatment decisions need a baseline and a trend. A rising PSA warrants urological evaluation before continuing.[2]

Hematocrit. Testosterone stimulates red blood cell production, and older men are more susceptible to the hematocrit rising too far. A complete blood count before and during treatment is standard.

Sleep apnea. More common with age, and it both worsens with testosterone and independently suppresses it. Worth screening before starting.

Cardiovascular baseline. TRAVERSE found testosterone did not increase major adverse cardiac events versus placebo in men with existing cardiovascular disease or high risk,[1] but a baseline blood pressure and lipid panel is still the sensible starting point at this age.

When starting is not appropriate

These are provider conversations, not self-screening criteria:

• Active prostate cancer
• A recent heart attack, stroke, or major cardiac procedure — defer until stable
• Hematocrit already elevated before treatment — address that first
• Severe untreated sleep apnea — treat that first
• A wish to preserve fertility — testosterone therapy suppresses sperm production

Frequently asked questions

Is it too late to start in my sixties or seventies? Age alone is not a contraindication, and the major trial evidence comes from men in this range — TRAVERSE enrolled men up to 80.[1] The relevant questions are whether hypogonadism is confirmed on two morning tests, whether contraindications are present, and whether a monitoring plan is in place.

Does TRT protect my bones? The best current evidence says no. The TRAVERSE fracture study found more fractures in treated men, not fewer.[3] Bone protection is not a reason to start testosterone.

My total testosterone is normal but I have symptoms. What now? Ask whether free testosterone and SHBG were measured. After 50 that is where a deficiency most often hides.[2]

Starting with an evaluation

If you are over 50 with fatigue, mood changes, body composition shifts, or reduced libido, a testosterone panel is a reasonable starting point — and it should include free testosterone and SHBG, not total alone.

Keen connects you with a licensed clinical team for a telehealth consultation and lab review. If your testosterone is clinically low, treatment is Keen Testosterone Spray Rx — a once-daily topical spray powered by Hypospray® transdermal delivery.

Related reading: low testosterone and fatigue and the TRAVERSE trial explained.

References

3 sources

1. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107–117. doi:10.1056/NEJMoa2215025 · PMID 37326322
2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
3. Snyder PJ, Bauer DC, Ellenberg SS, et al. Testosterone Treatment and Fractures in Men with Hypogonadism. N Engl J Med. 2024;390(3):203–211. doi:10.1056/NEJMoa2308836 · PMID 38231621